Contraindications to Phentermine Prescribing

Absolute Contraindications

• The American Gastroenterological Association recommends avoiding phentermine in patients with a history of cardiovascular disease, including coronary artery disease, stroke, arrhythmias, or congestive heart failure, due to the lack of large cardiovascular outcome trial data for long-term use 1, 2
• Phentermine should not be prescribed to patients with uncontrolled hypertension, as it may elevate blood pressure 1
• The American Gastroenterological Association guidelines state that phentermine should be avoided in patients with untreated hyperthyroidism due to concerns for arrhythmias and seizures 1
• Phentermine is contraindicated in patients with a history of drug abuse, as it is a Schedule IV controlled substance with abuse and dependence potential 3
• The FDA labeling and guidelines recommend avoiding phentermine in patients currently using or within 14 days of monoamine oxidase inhibitors (MAOIs) due to the risk of hypertensive crisis 1

Relative Contraindications and High-Risk Situations

• Patients requiring general anesthesia require special management considerations when taking phentermine 1
• The American Gastroenterological Association recommends exercising caution when prescribing phentermine to patients with seizure disorders, particularly when combined with other medications 2

Pregnancy and Lactation - Absolute Contraindications

• Women of childbearing potential should be counseled about contraception when taking phentermine, particularly when combined with topiramate, which is teratogenic 4

Critical Screening Errors

• Failing to obtain a complete cardiovascular history, including remote history of arrhythmias or structural heart disease, is a critical screening error when prescribing phentermine 1
• Inadequate assessment of thyroid function before initiation of phentermine is a critical screening error 1

Phentermine Use in Patients with Controlled Hyperthyroidism

Cardiovascular Considerations

• Phentermine activates the sympathetic nervous system, causing mild increases in heart rate and blood pressure, which can create additive cardiovascular stress, particularly regarding arrhythmia risk, in patients with controlled hyperthyroidism 5
• The American Gastroenterological Association recommends ongoing cardiovascular monitoring, including blood pressure and heart rate, at every visit throughout treatment, for patients with controlled hyperthyroidism taking phentermine 5

Phentermine Contraindication in Patients with Atrial Fibrillation (including those with Pacemakers)

Guideline Recommendations

Mechanistic Rationale for Arrhythmia Risk

Safer Alternative Weight‑Loss Options

Indications for Graded Exercise Stress Testing Prior to Phentermine Initiation

General Indication

• The American College of Cardiology recommends that a graded exercise stress test be performed before starting phentermine in adults ≥ 35 years who have diabetes mellitus, two or more cardiovascular risk factors (elevated cholesterol, hypertension, smoking, family history of premature coronary disease), or any cardiovascular symptoms, especially when moderate‑to‑high intensity physical activity is planned. 8, 9, 10

High‑Risk Demographic Groups

• American College of Cardiology and American Heart Association advise that men ≥ 45 years and women ≥ 55 years with diabetes mellitus or ≥ 2 cardiovascular risk factors who intend to engage in moderate‑to‑vigorous exercise should undergo graded exercise testing. 8, 10
• American College of Cardiology and American Diabetes Association state that any adult ≥ 35 years with diabetes mellitus planning vigorous exercise requires a stress test. 8, 9
• American College of Cardiology defines “multiple cardiovascular risk factors” as the presence of elevated total cholesterol, elevated blood pressure, current smoking, diabetes, or a first‑degree relative with early myocardial infarction or sudden cardiac death; patients meeting any of these criteria should be screened with exercise testing. 8
• American Heart Association requires that any patient presenting with cardiovascular symptoms such as exertional chest pain, dyspnea, palpitations, or unexplained fatigue undergo stress testing before phentermine initiation. 10

Diabetes‑Specific Testing Criteria

• American Diabetes Association considers exercise stress testing reasonable for asymptomatic adults with diabetes aged ≥ 35 years who plan moderate‑to‑high intensity activity. 9
• American Diabetes Association recommends testing for patients with long‑standing diabetes: type 2 duration ≥ 10 years or type 1 duration ≥ 15 years. 9
• American Diabetes Association advises testing when microvascular complications are present (e.g., proliferative retinopathy, nephropathy with microalbuminuria). 9
• American Diabetes Association also recommends testing for patients with peripheral vascular disease or autonomic neuropathy. 9

Multiple Risk‑Factor Assessment

• American Heart Association suggests that an exercise ECG may be considered for intermediate‑risk asymptomatic adults, with particular attention to non‑ECG markers such as exercise capacity. 11
• American Heart Association specifies that men > 45 years and women > 55 years with ≥ 2 risk factors planning vigorous exercise should receive a medical evaluation that includes exercise stress testing. 10
• American College of Cardiology notes that a Framingham risk score indicating at least a moderate 5‑year risk of serious cardiac events supports the decision to perform stress testing. 8

Symptomatic Patients

• American Heart Association requires that any patient with exertional chest pain, dyspnea, palpitations, or fatigue undergo graded exercise stress testing before initiating phentermine. 10

Cardiovascular Contraindications for Phentermine

Left Ventricular Hypertrophy as a Specific Contraindication

• Severe left ventricular hypertrophy is listed as an explicit contraindication for certain anti‑arrhythmic medications in the European Society of Cardiology (ESC) guidelines, reflecting the heightened risk of arrhythmias in this population. Evidence strength: guideline recommendation (2024). 12

Lack of Safety Data in High‑Risk Cardiac Populations

• All major clinical trials of phentermine excluded participants with any form of cardiovascular disease, resulting in no evidence of safety for patients with coronary artery ectasia or left ventricular hypertrophy. Evidence strength: absence of data (Gastroenterology trial summary, 2017). 13